MNPR earnings: a negative outcome, -7.6%

On March 28, 2024, Monopar Therapeutics reached its earnings. The result was a negative outcome, and the stock moved -7.6% in the window around the event. It had already run -41.3% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.